Cytosorbents (CTSO) Reports FY18 Loss of $0.56
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
March 7, 2019 4:15 PM ESTMONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record total revenue, CytoSorb® sales, and product gross margins in 2018.
... More